Comparison between induced platelet aggregation and circulating platelet aggregates as platelet function tests in...

Area of Science:

• Hematology
• Neurology
• Pharmacology

Background:

• Platelet aggregation plays a crucial role in thrombotic events, including transient ischemic attacks (TIA).
• Understanding platelet function and the impact of prophylactic treatments is essential for stroke prevention.

Purpose of the Study:

• To investigate routine blood parameters, platelet counts, circulating platelet aggregates (CPA), and in vitro platelet aggregation.
• To compare findings in healthy controls, non-stroke neurological patients, and TIA patients.
• To evaluate the effects of anticoagulant (AC) and antiplatelet drug (APD) therapies on platelet function.

Main Methods:

• Blood samples were analyzed for routine parameters, platelet counts, CPA, and in vitro aggregation induced by ADP, epinephrine, and collagen.
• Studies were conducted on 45 healthy controls, 10 non-stroke neurological patients, and 12 TIA patients.
• TIA patients were assessed before and after prophylactic treatment with AC or APD.

Main Results:

• Smoking females using oral contraceptives showed increased CPA and heightened in vitro aggregation.
• TIA patients did not exhibit significant differences in blood or platelet findings compared to controls, despite some individuals showing high CPA and aggregation.
• APD therapy significantly decreased CPA and inhibited secondary platelet aggregation in vitro; AC therapy showed no effect on platelet function.

Conclusions:

• Antiplatelet drug (APD) therapy effectively reduces circulating platelet aggregates and inhibits platelet aggregation.
• Anticoagulant (AC) therapy does not influence platelet function.
• Findings suggest APD is a more direct intervention for modulating platelet activity relevant to TIA.